Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Secondary Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Secondary Neoplasm

Cancer Family

Secondary Neoplasm

CI-CAN-00000050Explore in graph →

Non-malignant4,276 active trials56 approved drugs532 evidence items

NCIt: C36255

Overview
Statistics
Survival
Genomics199
Variants & evidence532
Drugs130
Trials14673
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (486)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 201–225 of 486 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases.
· Mod Pathol · 2019 · PMID 30980040 · validated civic_curation pubmed
SMARCB1/INI1 inactivation in renal medullary carcinoma.
· Histopathology · 2012 · PMID 22686875 · validated civic_curation pubmed
Fibroblast Growth Factor Receptor Family Members as Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review.
· Target Oncol · 2016 · PMID 26115874 · validated civic_curation pubmed
Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China.
· Cancer Biomark · 2017 · PMID 28269754 · validated civic_curation pubmed
Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations.
· J Thorac Oncol · 2012 · PMID 22895145 · validated civic_curation pubmed
EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.
· Mol Cancer Ther · 2013 · PMID 23371856 · validated civic_curation pubmed
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
· Sci Transl Med · 2013 · PMID 24353160 · validated civic_curation

Showing 201–225 of 486 publications

← Previous
1
…
8
9
10
…
20
Next →

Successful treatment with weekly high-dose erlotinib against meningeal metastases from epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma.

· Respir Investig · 2016 · PMID 27566387 · validated civic_curation pubmed

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

· N Engl J Med · 2010 · PMID 20979473 · validated civic_curation pubmed

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

· Sci Transl Med · 2012 · PMID 22277784 · validated civic_curation pubmed

Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.

· JAMA Oncol · 2015 · PMID 26181029 · validated civic_curation pubmed

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.

· Ann Oncol · 2016 · PMID 26598547 · validated civic_curation pubmed

Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer.

· Lung Cancer · 2015 · PMID 25601188 · validated civic_curation pubmed

HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.

· Lung Cancer · 2015 · PMID 26559459 · validated civic_curation pubmed

Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.

· Int J Gynaecol Obstet · 2008 · PMID 18555254 · validated civic_curation pubmed

Acquired resistance to crizotinib from a mutation in CD74-ROS1.

· N Engl J Med · 2013 · PMID 23724914 · validated civic_curation pubmed

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib.

· Case Rep Oncol · 2014 · PMID 24987354 · validated civic_curation pubmed

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.

· J Clin Oncol · 2015 · PMID 26324360 · validated civic_curation pubmed

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.

· Cancer Discov · 2016 · PMID 26546295 · validated civic_curation pubmed

Genotype-phenotype correlations in von Hippel-Lindau disease.

· Hum Mutat · 2007 · PMID 17024664 · validated civic_curation pubmed

Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.

· Cancer Discov · 2014 · PMID 24934408 · validated civic_curation pubmed

NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer.

· Cancer Discov · 2018 · PMID 29802158 · validated civic_curation pubmed

Selective RET kinase inhibition for patients with RET-altered cancers.

· Ann Oncol · 2018 · PMID 29912274 · validated civic_curation pubmed

Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic DPYD structural variant.

· Cold Spring Harb Mol Case Stud · 2020 · PMID 31871216 · validated civic_curation pubmed

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.

· J Thorac Oncol · 2020 · PMID 31988000 · validated civic_curation pubmed